Aberrant Expression of Interleukin-1β and Inflammasome Activation in Human Malignant Gliomas
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glioblastoma is the most frequent and malignant form of primary brain tumor with grave prognosis. Mounting evidence supports that chronic inflammation (such as chronic overactivation of IL-1 system) is a crucial event in carcinogenesis and tumor progression. IL-1 also is an important cytokine with species-dependent regulations and roles in CNS cell activation. While much attention is paid to specific anti-tumor immunity, little is known about the role of chronic inflammation/innate immunity in glioma pathogenesis. In this study, we examined whether human astrocytic cells (including malignant gliomas) can produce IL-1 and its role in glioma progression. METHODS: We used a combination of cell culture, real-time PCR, ELISA, western blot, immunocytochemistry, siRNA and plasmid transfection, micro-RNA analysis, angiogenesis (tube formation) assay, and neurotoxicity assay. RESULTS: Glioblastoma cells produced large quantities of IL-1 when activated, resembling macrophages/microglia. The activation signal was provided by IL-1 but not the pathogenic components LPS or poly IC. Glioblastoma cells were highly sensitive to IL-1 stimulation, suggesting its relevance in vivo. In human astrocytes, IL-1β mRNA was not translated to protein. Plasmid transfection also failed to produce IL-1 protein, suggesting active repression. Suppression of microRNAs that can target IL-1α/β did not induce IL-1 protein. Glioblastoma IL-1β processing occurred by the NLRP3 inflammasome, and ATP and nigericin increased IL-1β processing by upregulating NLRP3 expression, similar to macrophages. RNAi of annexin A2, a protein strongly implicated in glioma progression, prevented IL-1 induction, demonstrating its new role in innate immune activation. IL-1 also activated Stat3, a transcription factor crucial in glioma progression. IL-1 activated glioblastoma-conditioned media enhanced angiogenesis and neurotoxicity. CONCLUSIONS: Our results demonstrate unique, species-dependent immune activation mechanisms involving human astrocytes and astrogliomas. Specifically, the ability to produce IL-1 by glioblastoma cells may confer them a mesenchymal phenotype including increased migratory capacity, unique gene signature and proinflammatory signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 1×
“Recent advances in cancer genomics/genetics have shown molecular subclassification of GBM that correlates with prognosis [81,82].”
BackgroundImmunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466
Inflammasomes in health and disease
Strowig, T., Henao-Mejia, J., Elinav, E., & Flavell, R. (2012) · Nature · doi:10.1038/nature10759 · Cited by 2,230 · cited 1×
“The cleavage and release of bioactive IL-1b in myeloid cells is mediated by the inflammasomes, cytosolic caspase-1 activating tri-molecular complexes consisting of pro-caspase-1, the adaptor protein ASC and a NLRP3 (or AIM) protein [47].”
BackgroundThe brain tumor microenvironment
Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R., & Kettenmann, H. (2011) · Glia · doi:10.1002/glia.21136 · Cited by 718
Bauernfeind, F., Bartok, E., Rieger, A., Franchi, L., Núñez, G., & Hornung, V. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100613 · Cited by 617 · cited 1×
“In macrophages, baseline NLRP3 protein expression is minimal and upregulation of NLRP3 is the (possibly only) critical step involved in inflammasome activation [43,74].”
BackgroundInflammasomes in carcinogenesis and anticancer immune responses
Zitvogel, L., Kepp, O., Galluzzi, L., & Kroemer, G. (2012) · Nature Immunology · doi:10.1038/ni.2224 · Cited by 593 · cited 1×
“been considered a tumor promoting condition, arguing in favor of IL-1b inhibition for tumor prevention or therapy [15,17].”
BackgroundMolecular Mechanism of NLRP3 Inflammasome Activation
Jin, C., & Flavell, R. A. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9440-3 · Cited by 440
The role of microglia in central nervous system immunity and glioma immunology
Yang, I., Han, S. J., Kaur, G., Crane, C., & Parsa, A. T. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2009.05.006 · Cited by 410
Butovsky, O., Koronyo-Hamaoui, M., Kunis, G., Ophir, E., Landa, G., Cohen, H., & Schwartz, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604681103 · Cited by 388 · cited 1×
“IL-1 has additional deleterious effects such as induction of seizure activity [84,85] and suppression of neuronal growth factor production from microglia [25,86], indicating additional pathways glioma-induced IL-1 can negatively”
BackgroundMicroRNA-146a: A Key Regulator of Astrocyte-Mediated Inflammatory Response
Iyer, A., Zurolo, E., Prabowo, A., Fluiter, K., Spliet, W. G. M., van Rijen, P. C., Gorter, J. A., & Aronica, E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044789 · Cited by 330
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Epidemiology of Glioblastoma Multiforme–Literature Review
Grochans, S., Cybulska, A. M., Simińska, D., Korbecki, J., Kojder, K., Chlubek, D., & Baranowska-Bosiacka, I. (2022) · Cancers · doi:10.3390/cancers14102412 · Cited by 630
Role of the NLRP3 inflammasome in cancer
Moossavi, M., Parsamanesh, N., Bahrami, A., Atkin, S. L., & Sahebkar, A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0900-3 · Cited by 417
NLRP3 inflammasome is expressed and functional in mouse brain microglia but not in astrocytes
Gustin, A., Kirchmeyer, M., Koncina, E., Felten, P., Losciuto, S., Heurtaux, T., Tardivel, A., Heuschling, P., & Dostert, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130624 · Cited by 369
Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells
WANG, Y., KONG, H., ZENG, X., LIU, W., WANG, Z., YAN, X., WANG, H., & XIE, W. (2016) · Oncology Reports · doi:10.3892/or.2016.4569 · Cited by 186
Role of pattern recognition receptors of the neurovascular unit in inflamm-aging
Wilhelm, I., Nyúl-Tóth, Á., Kozma, M., Farkas, A. E., & Krizbai, I. A. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00106.2017 · Cited by 56
Moraes, C. A., Hottz, E. D., Dos Santos Ornellas, D., Adesse, D., de Azevedo, C. T., d’Avila, J. C., Zaverucha-do-Valle, C., Maron-Gutierrez, T., Barbosa, H. S., Bozza, P. T., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-022-03067-z · Cited by 43
Hyperbaric oxygen therapy sensitizes nimustine treatment for glioma in mice
Lu, Z., Ma, J., Liu, B., Dai, C., Xie, T., Ma, X., Li, M., Dong, J., Lan, Q., & Huang, Q. (2016) · Cancer Medicine · doi:10.1002/cam4.851 · Cited by 42
“[25] that glioma cells also had high expression of IL- 1β.”
Background
Metadata
- Authors
- Tarassishin, L., Casper, D., & Lee, S. C.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-07-23
- Volume
- 9
- Issue
- 7
- Pages
- e103432
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1979776162
- Cited by
- 96
- References
- 12
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.